By binding to GLP-1 receptors, semaglutide helps enhance insulin release, suppress glucagon secretion, slow gastric emptying, and increase feelings of fullness
GLP-1 agonists provide benefits by stimulating receptors that react to a hormone called glucagon-like peptide 1
Mean percent changes from baseline at Week 24 were 0.0% versus 2.5% for total cholesterol, and -1.0% versus 2.9% for LDL cholesterol in the placebo and dapagliflozin 10 mg groups, respectively
Follow-up windows were not prespecified, and HbA1c and weight reflect the most recent available clinical measurements with heterogeneous follow-up duration
Glucagon-Like Peptide-1 Protects Beta-Cells Against Apoptosis by Increasing the Activity of an IGF-2/IGF-1 Receptor Autocrine Loop
Glucagon-Like Peptide-1 agonists, more commonly known as GLP-1 medications, were originally developed to help regulate blood sugar in people with type 2 diabetes